BALTIMORE, January 29, 2019 – Elixirgen Scientific’s Quick-Muscle™ Skeletal – SeV Complete Kit (QMS-SeV) was used in a paper that was recently published in Molecular Therapy. Dr. Guangbin Xia (University of New Mexico)’s publication, “Therapeutic Genome Editing for Myotonic Dystrophy Type 1 Using CRISPR/Cas9” presents his results using CRISPR/Cas9 genome editing and induced pluripotent stem […]
CIRM (California Institute for Regenerative Medicine) has featured Elixirgen Scientific on their blog. Visit CIRM’s “the Stem Cellar” article to see the content.
Elixirgen Scientific has begun selling a variety of cell-based human disease models after signing a new agreement, which allows the company to produce and distribute cells differentiated from the California Institute for Regenerative Medicine (CIRM)’s human pluripotent stem cell (hPSC) repository
Quick-Tissue™ Series users can now see how simple protocols are from Elixirgen Scientific’s first protocol video on YouTube.
Elixirgen Scientific’s new kit option for Quick-Neuron™ Cholinergic enables high throughput screening for drug discovery and toxicity screening.
Elixirgen Scientific can make global Alzheimer’s disease, Parkinson’s disease, and other brain research faster and better.
Elixirgen Scientific’s new mixed neuron cell differentiation kit will accelerate mini-brain projects including 3D bioprinting and tissue chip development.
Elixirgen Scientific released Quick-Tissue™ Mesoderm Booster and Quick-Tissue™ Endoderm Booster. These new products accelerates human pluripotent stem cell (hPSC) differentiation into tissues from the mesoderm and endoderm layers.
Elixirgen Scientific reached an agreement with CIEA (Central Institute for Experimental Animals), an industry-leading experimental animal model developer, to conduct joint research for developing humanized NOG mice with Quick-Tissue™ technology.
Stop waiting months for tissues! Elixirgen Scientific provides pluripotent stem cell differentiation services with the world’s fastest turnaround time.
Elixirgen Scientific reached an agreement with Scrum Inc., one of top Japanese life science distribution agencies to distribute Quick-Tissue Series and provide cell differentiation services
Elixirgen Scientific can make global Alzheimer’s disease, Parkinson’s disease, and Muscular Dystrophy research faster and better.
Elixirgen Scientific, through its parent company, Elixirgen, LLC, has entered into a license agreement with ID Pharma Co., Ltd., a wholly owned subsidiary of the I’Rom Group (TYO: 2372) for Sendai Virus Vector technology.
Quick-Neuron™ Cholinergic is based on technology licensed from Keio University. The original paper has just been published in Scientific Reports.
Elixirgen Scientific launched Quick-Muscle™ Skeletal, which differentiates stem cells and induced pluripotent stem cells (iPSCs) into skeletal muscle cells in less than one week.